Nonacog alfa
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hemophilia B
Conditions
Hemophilia B
Trial Timeline
Feb 10, 2020 → Sep 24, 2020
NCT ID
NCT04286412About Nonacog alfa
Nonacog alfa is a approved stage product being developed by Pfizer for Hemophilia B. The current trial status is completed. This product is registered under clinical trial identifier NCT04286412. Target conditions include Hemophilia B.
What happened to similar drugs?
20 of 20 similar drugs in Hemophilia B were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04286412 | Approved | Completed |
Competing Products
20 competing products in Hemophilia B
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 40 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 40 |
| Emicizumab + rFVIIa + aPCC | Chugai Pharmaceutical | Phase 3 | 40 |
| Human Coagulation Factor VIII | Chugai Pharmaceutical | Phase 3 | 47 |
| Emicizumab | Chugai Pharmaceutical | Phase 3 | 47 |
| Emicizumab + Factor VIII (FVIII) | Chugai Pharmaceutical | Phase 3 | 40 |
| Emicizumab | Roche | Phase 3 | 40 |
| HEMLIBRA | Johnson & Johnson | Pre-clinical | 26 |
| Emicizumab | Roche | Phase 3 | 40 |
| Emicizumab | Roche | Approved | 47 |
| Emicizumab | Roche | Phase 3 | 44 |
| SPK-8011QQ | Roche | Phase 1/2 | 39 |
| NXT007 | Roche | Phase 1/2 | 39 |
| Emicizumab Injection | Roche | Phase 2 | 35 |
| Bypassing Agents + FVIII Replacement | Roche | Pre-clinical | 26 |
| PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086 | Pfizer | Phase 2 | 35 |
| Nonacog Alfa (Genetical Recombination) | Pfizer | Pre-clinical | 26 |
| Refacto AF | Pfizer | Pre-clinical | 18 |
| PF-06838435/ fidanacogene elaparvovec | Pfizer | Phase 3 | 44 |
| ReFacto AF | Pfizer | Phase 3 | 40 |